{"name":"Fresenius Kabi","slug":"fresenius-kabi","ticker":"FRE.DE","exchange":"Frankfurt Stock Exchange","domain":"fresenius-kabi.com","description":"Fresenius SE & Co. KGaA is a German multinational health care company based in Bad Homburg vor der Höhe. It provides products and services for dialysis in hospitals, as well as inpatient and outpatient medical care. The company is involved in hospital management and in engineering and services for medical centers and other health care facilities. The company was ranked 411th in the 2023 Forbes Global 2000 list.","hq":"Bad Homburg, Germany","founded":1911,"employees":"177783","ceo":"Michael Sen (Fresenius SE CEO)","sector":"Biosimilars / IV Drugs / Clinical Nutrition","stockPrice":39.07,"stockChange":0.74,"stockChangePercent":1.93,"marketCap":"$25.7B","metrics":{"revenue":26849666619.345715,"revenueGrowth":2,"grossMargin":25.3,"rdSpend":0,"netIncome":1768484929.1999998,"cash":2405092854.957619,"dividendYield":2.74,"peRatio":14.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1939-01-01","label":"Heparin Sodium In Plastic Container first approved","drug":"Heparin Sodium In Plastic Container","drugSlug":"heparin-sodium-25-000-units-in-dextrose-5-in-plastic-container","type":"approval","sentiment":"positive"},{"date":"1939-01-01","label":"Heparin Sodium In Plastic Container first approved","drug":"Heparin Sodium In Plastic Container","drugSlug":"heparin-sodium-10-000-units-in-dextrose-5-in-plastic-container","type":"approval","sentiment":"positive"},{"date":"1939-01-01","label":"Heparin Sodium In Plastic Container first approved","drug":"Heparin Sodium In Plastic Container","drugSlug":"heparin-sodium-preservative-free","type":"approval","sentiment":"positive"},{"date":"1939-01-01","label":"Heparin Sodium In Plastic Container first approved","drug":"Heparin Sodium In Plastic Container","drugSlug":"heparin-sodium-12-500-units-in-dextrose-5-in-plastic-container","type":"approval","sentiment":"positive"},{"date":"1939-01-01","label":"Heparin Sodium In Plastic Container first approved","drug":"Heparin Sodium In Plastic Container","drugSlug":"heparin-sodium","type":"approval","sentiment":"positive"},{"date":"1948-01-01","label":"Lignospan Forte first approved","drug":"Lignospan Forte","drugSlug":"lidocaine-hydrochloride-in-plastic-container","type":"approval","sentiment":"positive"},{"date":"1948-01-01","label":"Lignospan Forte first approved","drug":"Lignospan Forte","drugSlug":"lidocaine-hydrochloride","type":"approval","sentiment":"positive"},{"date":"1955-01-01","label":"Nesacaine-Mpf first approved","drug":"Nesacaine-Mpf","drugSlug":"chloroprocaine","type":"approval","sentiment":"positive"},{"date":"1980-01-01","label":"Oxytocin 5 Usp Units In Dextrose 5% first approved","drug":"Oxytocin 5 Usp Units In Dextrose 5%","drugSlug":"oxytocin","type":"approval","sentiment":"positive"},{"date":"1984-01-01","label":"Dilaudid-Hp first approved","drug":"Dilaudid-Hp","drugSlug":"hydromorphone-hydrochloride","type":"approval","sentiment":"positive"},{"date":"1984-01-01","label":"Dilaudid-Hp first approved","drug":"Dilaudid-Hp","drugSlug":"hydromorphone","type":"approval","sentiment":"positive"},{"date":"1984-01-01","label":"Pentam first approved","drug":"Pentam","drugSlug":"pentamidine","type":"approval","sentiment":"positive"},{"date":"1989-01-01","label":"Diprivan first approved","drug":"Diprivan","drugSlug":"propofol","type":"approval","sentiment":"positive"},{"date":"1994-01-01","label":"Zemuron first approved","drug":"Zemuron","drugSlug":"rocuronium","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Naropin first approved","drug":"Naropin","drugSlug":"ropivacaine","type":"approval","sentiment":"positive"},{"date":"2000-01-01","label":"Unithroid first approved","drug":"Unithroid","drugSlug":"levothyroxine-sodium","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Tygacil first approved","drug":"Tygacil","drugSlug":"tigecycline","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Bloxiverz first approved","drug":"Bloxiverz","drugSlug":"neostigmine","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Perikabiven In Plastic Container first approved","drug":"Perikabiven In Plastic Container","drugSlug":"sodium-glycerophosphate","type":"approval","sentiment":"positive"},{"date":"2026-07-24","label":"Lignospan Forte patent expiry (Formulation)","drug":"Lignospan Forte","drugSlug":"lidocaine-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"STIMUFEND Phase 3 readout (Primary Mediastinal Large B-Cell Lymphoma)","drug":"STIMUFEND","drugSlug":"pegfilgrastim-fpgk","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-09-30","label":"STIMUFEND Phase 2 readout (Renal Pelvis and Ureter Urothelial Carcinoma)","drug":"STIMUFEND","drugSlug":"pegfilgrastim-fpgk","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-10-22","label":"Lignospan Forte patent expiry (Method of Use)","drug":"Lignospan Forte","drugSlug":"lidocaine-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2031-08-06","label":"Unithroid patent expiry (Formulation)","drug":"Unithroid","drugSlug":"levothyroxine-sodium","type":"patent_expiry","sentiment":"negative"},{"date":"2032-08-29","label":"Unithroid patent expiry (Formulation)","drug":"Unithroid","drugSlug":"levothyroxine-sodium","type":"patent_expiry","sentiment":"negative"},{"date":"2032-08-29","label":"Unithroid patent expiry (Formulation)","drug":"Unithroid","drugSlug":"levothyroxine-sodium","type":"patent_expiry","sentiment":"negative"},{"date":"2032-10-03","label":"Unithroid patent expiry (Formulation)","drug":"Unithroid","drugSlug":"levothyroxine-sodium","type":"patent_expiry","sentiment":"negative"},{"date":"2035-02-27","label":"Unithroid patent expiry (Formulation)","drug":"Unithroid","drugSlug":"levothyroxine-sodium","type":"patent_expiry","sentiment":"negative"},{"date":"2035-04-27","label":"Lignospan Forte patent expiry (Method of Use)","drug":"Lignospan Forte","drugSlug":"lidocaine-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2035-09-28","label":"Lignospan Forte patent expiry (Method of Use)","drug":"Lignospan Forte","drugSlug":"lidocaine-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2036-07-20","label":"Unithroid patent expiry (Formulation)","drug":"Unithroid","drugSlug":"levothyroxine-sodium","type":"patent_expiry","sentiment":"negative"},{"date":"2037-02-28","label":"Unithroid patent expiry (Formulation)","drug":"Unithroid","drugSlug":"levothyroxine-sodium","type":"patent_expiry","sentiment":"negative"},{"date":"2037-02-28","label":"Unithroid patent expiry (Formulation)","drug":"Unithroid","drugSlug":"levothyroxine-sodium","type":"patent_expiry","sentiment":"negative"},{"date":"2038-03-23","label":"Unithroid patent expiry (Formulation)","drug":"Unithroid","drugSlug":"levothyroxine-sodium","type":"patent_expiry","sentiment":"negative"},{"date":"2038-03-23","label":"Unithroid patent expiry (Formulation)","drug":"Unithroid","drugSlug":"levothyroxine-sodium","type":"patent_expiry","sentiment":"negative"},{"date":"2039-09-17","label":"Unithroid patent expiry (Method of Use)","drug":"Unithroid","drugSlug":"levothyroxine-sodium","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Voluven patent cliff ($1.2B at risk)","drug":"Voluven","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"SmofKabiven patent cliff ($800M at risk)","drug":"SmofKabiven","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"neuroscience","drugs":[{"name":"Ionolyte","genericName":"Ionolyte","slug":"ionolyte","indication":"Other","status":"marketed"},{"name":"Ketosteril®","genericName":"Ketosteril®","slug":"ketosteril","indication":"Other","status":"marketed"},{"name":"Perikabiven In Plastic Container","genericName":"SODIUM GLYCEROPHOSPHATE","slug":"sodium-glycerophosphate","indication":"Hypophosphatemia","status":"marketed"},{"name":"Volulyte 6%","genericName":"Volulyte 6%","slug":"volulyte-6","indication":"Other","status":"marketed"},{"name":"Compounded standard parenteral nutrition","genericName":"Compounded standard parenteral nutrition","slug":"compounded-standard-parenteral-nutrition","indication":"Other","status":"marketed"},{"name":"EU-Humira","genericName":"EU-Humira","slug":"eu-humira","indication":"Other","status":"phase_3"},{"name":"IDACIO","genericName":"ADALIMUMAB-AACF","slug":"adalimumab-aacf","indication":"Other","status":"marketed"},{"name":"Lactulose crystals 30 g","genericName":"Lactulose crystals 30 g","slug":"lactulose-crystals-30-g","indication":"Other","status":"marketed"},{"name":"Lactulose liquid 20 g","genericName":"Lactulose liquid 20 g","slug":"lactulose-liquid-20-g","indication":"Other","status":"marketed"},{"name":"OTULFI","genericName":"USTEKINUMAB-AAUZ","slug":"ustekinumab-aauz","indication":"Other","status":"marketed"},{"name":"Oxytocin 5 Usp Units In Dextrose 5%","genericName":"OXYTOCIN","slug":"oxytocin","indication":"Incomplete miscarriage","status":"marketed"},{"name":"STIMUFEND","genericName":"PEGFILGRASTIM-FPGK","slug":"pegfilgrastim-fpgk","indication":"Other","status":"marketed"},{"name":"SmofKabiven® E","genericName":"SmofKabiven® E","slug":"smofkabiven-e","indication":"Other","status":"marketed"},{"name":"TYENNE","genericName":"TOCILIZUMAB-AAZG","slug":"tocilizumab-aazg","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Heparin Sodium In Plastic Container","genericName":"Heparin Sodium","slug":"heparin-sodium-25-000-units-in-dextrose-5-in-plastic-container","indication":"Deep Vein Thrombosis with Pulmonary Embolism","status":"marketed"},{"name":"Heparin Sodium In Plastic Container","genericName":"Heparin Sodium","slug":"heparin-sodium-10-000-units-in-dextrose-5-in-plastic-container","indication":"Deep Vein Thrombosis with Pulmonary Embolism","status":"marketed"},{"name":"Heparin Sodium In Plastic Container","genericName":"Heparin Sodium","slug":"heparin-sodium-preservative-free","indication":"Deep Vein Thrombosis with Pulmonary Embolism","status":"marketed"},{"name":"Heparin Sodium In Plastic Container","genericName":"Heparin Sodium","slug":"heparin-sodium-12-500-units-in-dextrose-5-in-plastic-container","indication":"Deep Vein Thrombosis with Pulmonary Embolism","status":"marketed"},{"name":"Heparin Sodium In Plastic Container","genericName":"Heparin Sodium","slug":"heparin-sodium","indication":"Deep Vein Thrombosis with Pulmonary Embolism","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"cardiovascular","drugs":[{"name":"Dilaudid-Hp","genericName":"Hydromorphone Hydrochloride","slug":"hydromorphone-hydrochloride","indication":"Acute postoperative pain","status":"marketed"},{"name":"Diprivan","genericName":"Propofol","slug":"propofol","indication":"General anesthesia","status":"marketed"},{"name":"Dilaudid-Hp","genericName":"HYDROMORPHONE","slug":"hydromorphone","indication":"Severe Pain Management","status":"marketed"},{"name":"Naropin","genericName":"ROPIVACAINE","slug":"ropivacaine","indication":"Anesthesia for cesarean section","status":"marketed"},{"name":"Nesacaine-Mpf","genericName":"CHLOROPROCAINE","slug":"chloroprocaine","indication":"Local anesthesia","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Lignospan Forte","genericName":"Lidocaine Hydrochloride","slug":"lidocaine-hydrochloride-in-plastic-container","indication":"Hemorrhoids","status":"marketed"},{"name":"Lignospan Forte","genericName":"Lidocaine Hydrochloride","slug":"lidocaine-hydrochloride","indication":"Hemorrhoids","status":"marketed"},{"name":"Tygacil","genericName":"TIGECYCLINE","slug":"tigecycline","indication":"Abdominal abscess","status":"marketed"},{"name":"Pentam","genericName":"PENTAMIDINE","slug":"pentamidine","indication":"African trypanosomiasis","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"MSB11456","genericName":"MSB11456","slug":"msb11456","indication":"HER2-positive breast cancer","status":"phase_3"},{"name":"MSB11022","genericName":"MSB11022","slug":"msb11022","indication":"HER2-positive breast cancer","status":"phase_3"},{"name":"US-licensed Prolia (Amgen)","genericName":"US-licensed Prolia (Amgen)","slug":"us-licensed-prolia-amgen","indication":"Treatment of osteoporosis in postmenopausal women at high risk of fracture, treatment to increase bone mass in men with osteoporosis, treatment to increase bone mass in women with osteoporosis due to sustained systemic glucocorticoid therapy, treatment of bone loss associated with hormone ablation in men with prostate cancer, treatment of bone loss in women with breast cancer, treatment of giant cell tumor of bone, treatment of hypercalcemia of malignancy, treatment of multiple myeloma, treatment of bone metastases in men with prostate cancer, treatment of bone metastases in women with breast cancer","status":"phase_3"},{"name":"Unithroid","genericName":"LEVOTHYROXINE SODIUM","slug":"levothyroxine-sodium","indication":"Congenital hypothyroidism","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"Zemuron","genericName":"ROCURONIUM","slug":"rocuronium","indication":"General anesthesia","status":"marketed"},{"name":"Bloxiverz","genericName":"NEOSTIGMINE","slug":"neostigmine","indication":"Myasthenia gravis","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"rare","drugs":[{"name":"EU-approved RoActemra","genericName":"EU-approved RoActemra","slug":"eu-approved-roactemra","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"FKS518","genericName":"FKS518","slug":"fks518","indication":"Organ transplant rejection prevention","status":"phase_3"}]}],"pipeline":[{"name":"Heparin Sodium In Plastic Container","genericName":"Heparin Sodium","slug":"heparin-sodium-25-000-units-in-dextrose-5-in-plastic-container","phase":"marketed","mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa.","indications":["Deep Vein Thrombosis with Pulmonary Embolism","Deep venous thrombosis","Disseminated intravascular coagulation","Maintain Patency of Indwelling Vascular Catheter","Non-Q wave myocardial infarction"],"catalyst":""},{"name":"Lignospan Forte","genericName":"Lidocaine Hydrochloride","slug":"lidocaine-hydrochloride-in-plastic-container","phase":"marketed","mechanism":"Lidocaine stabilizes neuronal membrane by inhibiting ionic fluxes required for impulse initiation and conduction.","indications":["Hemorrhoids","Infestation by Phthirus pubis","Infestation by Sarcoptes scabiei var hominis","Itching of skin","Local Anesthesia for Endotracheal Intubation"],"catalyst":""},{"name":"Dilaudid-Hp","genericName":"Hydromorphone Hydrochloride","slug":"hydromorphone-hydrochloride","phase":"marketed","mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation.","indications":["Acute postoperative pain","Chronic Pain with Opioid Tolerance","Common cold","Cough","Pain"],"catalyst":""},{"name":"Diprivan","genericName":"Propofol","slug":"propofol","phase":"marketed","mechanism":"Propofol produces sedative/anesthetic effects by positive modulation of inhibitory GABA function through GABA A receptors.","indications":["General anesthesia","Sedation as Adjunct to Anesthesia","Sedation in Intubated Patients"],"catalyst":""},{"name":"Heparin Sodium In Plastic Container","genericName":"Heparin Sodium","slug":"heparin-sodium-10-000-units-in-dextrose-5-in-plastic-container","phase":"marketed","mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa.","indications":["Deep Vein Thrombosis with Pulmonary Embolism","Deep venous thrombosis","Disseminated intravascular coagulation","Maintain Patency of Indwelling Vascular Catheter","Non-Q wave myocardial infarction"],"catalyst":""},{"name":"Heparin Sodium In Plastic Container","genericName":"Heparin Sodium","slug":"heparin-sodium-preservative-free","phase":"marketed","mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa.","indications":["Deep Vein Thrombosis with Pulmonary Embolism","Deep venous thrombosis","Disseminated intravascular coagulation","Maintain Patency of Indwelling Vascular Catheter","Non-Q wave myocardial infarction"],"catalyst":""},{"name":"Heparin Sodium In Plastic Container","genericName":"Heparin Sodium","slug":"heparin-sodium-12-500-units-in-dextrose-5-in-plastic-container","phase":"marketed","mechanism":"Heparin enhances Antithrombin III's activity to inhibit coagulation factors Xa and IIa, preventing clot formation.","indications":["Deep Vein Thrombosis with Pulmonary Embolism","Deep venous thrombosis","Disseminated intravascular coagulation","Maintain Patency of Indwelling Vascular Catheter","Non-Q wave myocardial infarction"],"catalyst":""},{"name":"Heparin Sodium In Plastic Container","genericName":"Heparin Sodium","slug":"heparin-sodium","phase":"marketed","mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa.","indications":["Deep Vein Thrombosis with Pulmonary Embolism","Deep venous thrombosis","Disseminated intravascular coagulation","Maintain Patency of Indwelling Vascular Catheter","Non-Q wave myocardial infarction"],"catalyst":""},{"name":"Lignospan Forte","genericName":"Lidocaine Hydrochloride","slug":"lidocaine-hydrochloride","phase":"marketed","mechanism":"Lidocaine stabilizes neuronal membrane by inhibiting ionic fluxes required for impulse initiation and conduction.","indications":["Hemorrhoids","Infestation by Phthirus pubis","Infestation by Sarcoptes scabiei var hominis","Itching of skin","Local Anesthesia for Endotracheal Intubation"],"catalyst":""},{"name":"Dilaudid-Hp","genericName":"HYDROMORPHONE","slug":"hydromorphone","phase":"marketed","mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect.","indications":["Severe Pain Management"],"catalyst":""},{"name":"Naropin","genericName":"ROPIVACAINE","slug":"ropivacaine","phase":"marketed","mechanism":"Sodium channel protein type 5 subunit alpha","indications":["Anesthesia for cesarean section","Local anesthesia","Major Nerve Block for Surgery","Regional Anesthesia for Labor Pain","Regional Anesthesia for Postoperative Pain"],"catalyst":""},{"name":"Tygacil","genericName":"TIGECYCLINE","slug":"tigecycline","phase":"marketed","mechanism":"Tygacil works by binding to the 30S ribosomal subunit of bacteria, preventing the aminoacyl-tRNA from binding and thereby inhibiting protein synthesis.","indications":["Abdominal abscess","Complicated Bacterial Peritonitis","Complicated Skin and Skin Structure E. Coli Infection","Complicated Skin and Skin Structure Enterococcus Faecalis Infection","Complicated Skin and Skin Structure Infection"],"catalyst":""},{"name":"Ionolyte","genericName":"Ionolyte","slug":"ionolyte","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ketosteril®","genericName":"Ketosteril®","slug":"ketosteril","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MSB11456","genericName":"MSB11456","slug":"msb11456","phase":"phase_3","mechanism":"MSB11456 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling.","indications":["HER2-positive breast cancer","HER2-positive gastric cancer"],"catalyst":""},{"name":"Perikabiven In Plastic Container","genericName":"SODIUM GLYCEROPHOSPHATE","slug":"sodium-glycerophosphate","phase":"marketed","mechanism":"","indications":["Hypophosphatemia"],"catalyst":""},{"name":"Volulyte 6%","genericName":"Volulyte 6%","slug":"volulyte-6","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Zemuron","genericName":"ROCURONIUM","slug":"rocuronium","phase":"marketed","mechanism":"Zemuron works by blocking the action of acetylcholine at the neuromuscular junction, preventing muscle contraction.","indications":["General anesthesia","Muscle relaxation, function","Skeletal Muscle Relaxation for Endotracheal Intubation"],"catalyst":""},{"name":"Bloxiverz","genericName":"NEOSTIGMINE","slug":"neostigmine","phase":"marketed","mechanism":"Bloxiverz works by blocking the enzyme acetylcholinesterase, allowing more acetylcholine to be available in the nervous system.","indications":["Myasthenia gravis","Retention of urine","Reversal of neuromuscular blockade"],"catalyst":""},{"name":"Compounded standard parenteral nutrition","genericName":"Compounded standard parenteral nutrition","slug":"compounded-standard-parenteral-nutrition","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EU-Humira","genericName":"EU-Humira","slug":"eu-humira","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EU-approved RoActemra","genericName":"EU-approved RoActemra","slug":"eu-approved-roactemra","phase":"phase_3","mechanism":"RoActemra (tocilizumab) is a humanized monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, reducing inflammatory signaling in immune-mediated diseases.","indications":["Rheumatoid arthritis","Giant cell arteritis","Polyarticular juvenile idiopathic arthritis","Systemic sclerosis-associated interstitial lung disease","COVID-19 (severe or critical)"],"catalyst":""},{"name":"FKS518","genericName":"FKS518","slug":"fks518","phase":"phase_3","mechanism":"FKS518 is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, thereby reducing immune-mediated rejection.","indications":["Organ transplant rejection prevention","Autoimmune diseases (investigational)"],"catalyst":""},{"name":"IDACIO","genericName":"ADALIMUMAB-AACF","slug":"adalimumab-aacf","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Lactulose crystals 30 g","genericName":"Lactulose crystals 30 g","slug":"lactulose-crystals-30-g","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lactulose liquid 20 g","genericName":"Lactulose liquid 20 g","slug":"lactulose-liquid-20-g","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MSB11022","genericName":"MSB11022","slug":"msb11022","phase":"phase_3","mechanism":"MSB11022 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and inhibiting tumor growth.","indications":["HER2-positive breast cancer","HER2-positive gastric cancer"],"catalyst":""},{"name":"Nesacaine-Mpf","genericName":"CHLOROPROCAINE","slug":"chloroprocaine","phase":"marketed","mechanism":"Sodium channel protein type 10 subunit alpha","indications":["Local anesthesia"],"catalyst":""},{"name":"OTULFI","genericName":"USTEKINUMAB-AAUZ","slug":"ustekinumab-aauz","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Oxytocin 5 Usp Units In Dextrose 5%","genericName":"OXYTOCIN","slug":"oxytocin","phase":"marketed","mechanism":"Oxytocin receptor","indications":["Incomplete miscarriage","Induction of labor","Postpartum hemorrhage","Pregnancy with abortive outcome"],"catalyst":""},{"name":"Pentam","genericName":"PENTAMIDINE","slug":"pentamidine","phase":"marketed","mechanism":"Pentamidine works by interfering with the reproduction of certain parasites, such as Pneumocystis jiroveci.","indications":["African trypanosomiasis","Pneumocystis Carinii Pneumonia Prevention","Pneumocystosis jiroveci pneumonia"],"catalyst":""},{"name":"STIMUFEND","genericName":"PEGFILGRASTIM-FPGK","slug":"pegfilgrastim-fpgk","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"SmofKabiven® E","genericName":"SmofKabiven® E","slug":"smofkabiven-e","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TYENNE","genericName":"TOCILIZUMAB-AAZG","slug":"tocilizumab-aazg","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"US-licensed Prolia (Amgen)","genericName":"US-licensed Prolia (Amgen)","slug":"us-licensed-prolia-amgen","phase":"phase_3","mechanism":"Prolia is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.","indications":["Treatment of osteoporosis in postmenopausal women at high risk of fracture, treatment to increase bone mass in men with osteoporosis, treatment to increase bone mass in women with osteoporosis due to sustained systemic glucocorticoid therapy, treatment of bone loss associated with hormone ablation in men with prostate cancer, treatment of bone loss in women with breast cancer, treatment of giant cell tumor of bone, treatment of hypercalcemia of malignancy, treatment of multiple myeloma, treatment of bone metastases in men with prostate cancer, treatment of bone metastases in women with breast cancer"],"catalyst":""},{"name":"Unithroid","genericName":"LEVOTHYROXINE SODIUM","slug":"levothyroxine-sodium","phase":"marketed","mechanism":"Unithroid works by replacing or supplementing the thyroid hormone thyroxine, which is produced by the thyroid gland.","indications":["Congenital hypothyroidism","Diagnostic Test for Thyroid Dysfunction","Goiter","Hashimoto thyroiditis","Hyperlipidemia"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Fresenius Kabi Receives FDA Approval for SmofKabiven E","summary":"Fresenius Kabi announced that it has received FDA approval for SmofKabiven E, a parenteral nutrition product.","drugName":"SmofKabiven E","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Fresenius Kabi Reports Strong Third-Quarter Results","summary":"Fresenius Kabi reported strong third-quarter results, with revenue growth driven by its biosimilars and IV drugs business.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPM083QTZjamg3THBPWHQwWTBxSXhJMkFXRzk2Uk5aVkxDb0lFQ1JTcmVBVjZzSDRVQ29QUUpLN3hPTmxEdldud0QzX0p2V3JEMUNKbDZzWFFrb3pJQjR2U0hkY3JTOTFaeGlHS3k2QTlMdFVmeWtHTTJGRlVteVJnRXJZSUZiY1VVTndCUjFQZTc3X19nY004RzN5VVZiem1PdzZldjllRlFnbzhVSXRiY0haOA?oc=5","date":"2026-04-01","type":"pipeline","source":"Yahoo Finance","summary":"Gemcitabine Hydrochloride Market Report 2026-2030 & 2035 Featuring Strategic Analysis of Fresenius Kabi, Eli Lilly and Company, Teva Pharma, Intas Pharma, Mylan and More - Yahoo Finance","headline":"Gemcitabine Hydrochloride Market Report 2026-2030 & 2035 Featuring Strategic Analysis of Fresenius Kabi, Eli Lilly and C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNTmxpUmlaMGhvdWw1TVJjd3pnT1NEUjR3WjA2dkZFQjdGMXpjZ3hLaFYyUlRrZlpsdUxHajgydDQzRUZpYTJqMmM5M0NXQ01jTmo2M05PaUV0Umt5QUJOYmFfcWpjY2FvTTJxa3MtbjZVSFJJbXhrOGxHUHdySTNYd0N1dGNxU0RKSXRtLTR6UDVnYjZKOElsNHNhRWRXdF9OcGoxYTNqREg4SHBQTVZxcHcwU0FQeEt3SWN1MGtUQWM?oc=5","date":"2026-03-31","type":"pipeline","source":"AD HOC NEWS","summary":"Fresenius Kabi's Fresubin Nutrition Products: Strategic Importance for Clinical Nutrition in North A - AD HOC NEWS","headline":"Fresenius Kabi's Fresubin Nutrition Products: Strategic Importance for Clinical Nutrition in North A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPLVAyalV1MkNzRnBLX1dKZmFsTkJ5aWlBeXhtN1BnMkx4ODRFS2VyQ3YzQkE0a0xIS2w3THZiN1hCNnB5dWZKWHlEbTVFZDZQaEVReEh3RUhpZmtsYWJELXhvVGoxTDB4TGd5M2hYVGM1SklvS1EyQ0MxT1g4cDNya09fYkJNQXRwZlV3ZnRLb1NvdWpBTHFVbjhDRU5sZk5XZUM2M1FSbUlub2draUlPcA?oc=5","date":"2026-02-10","type":"pipeline","source":"European Pharmaceutical Review","summary":"Fresenius Kabi and Phlow onshore US epinephrine manufacturing - European Pharmaceutical Review","headline":"Fresenius Kabi and Phlow onshore US epinephrine manufacturing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQM216a2F6dEl2MU9SdlRjLURrTFBLLTItNWdHektOanlTdlp0Z1hpRE5uZ3Ytemd0dktzbzlfRG00d1Y0MThXbi1XaFpkMmE3Q3IyR3RkdXMxeGF3eUg0Z3Bqbnc3bENXR3FYcGFDYlNnVkQ4c3E5RGcwOE5mSWlOZUFFODlfVTFiMXgtS0RDOXRNTHlNZUhVZjUxSFV3VDRaZWtGSDl5ekNtZHJfZUdyMENMSG5VbzRjb1ZQanFjRHZwSy1WX3k4?oc=5","date":"2026-02-09","type":"pipeline","source":"Fierce Pharma","summary":"Fresenius Kabi, Phlow ink US onshoring alliance to boost epinephrine injection supply - Fierce Pharma","headline":"Fresenius Kabi, Phlow ink US onshoring alliance to boost epinephrine injection supply","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNejRRZHRKM3VlZ1otRGhFWWFpSWNhMktwZmVYVUgzNEstc0VkZEx3LVpnNGg0WlhsTlAtODFQUW8tbHNaRG1HbFpocE1zdkxqZFlmU3RoeXQ1YmxWSzluYndod1NKdnF6Y242NllhRDE5Y2xYbVVxSmhTVnJGMHRKR185V19BbWxpUzFWZFd3NFI4YUpFNGd0ZTdHd1NqUk9rb2E5RW5faGJZN3EwVmdFOC0wQ3g4UVFSQ0p0SnUzdFJGYTBRNXVLNEpNRTDSAdMBQVVfeXFMTUVmRmZweFRkSDhwX1dEVl8yZVQ3SVVtUWJXdlFEaGtWQW54dFMtaTlMelBzTkxmZ240SHJsdmM0RXpkWFVzY1FCZzRUOVZ2VmFubWE1d1BNSGJueEtPSmgxZmJKNjU4YkV0RWp0R3NqRk5lSm1BUl9MT2hTVnFmNGZCWEZielU4ZVp6VmV2VUk2M0NzS2hwSWh3Y3BUOTRjekkycDgxQ3Z3UHJQYWV2RHFTNkRJaGdVVmUtT3pvbWt6dHV3VGZlQ1NhYW9lV1hNZmNrRQ?oc=5","date":"2026-01-21","type":"pipeline","source":"Indian Pharma Post","summary":"Fresenius Kabi & TQ Therapeutics join forces to accelerate cell & gene therapy manufacturing - Indian Pharma Post","headline":"Fresenius Kabi & TQ Therapeutics join forces to accelerate cell & gene therapy manufacturing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQX0hOQWhZQWRxVU8yRHR2T2VGZ1JRaGlmXy0wTXVlc3hha1FDNms4Z0VxNXl1TU9fVHJJMU9DZ010MWx0THBqaGVuUEZtOGtkbzdDLUd0SEd1N2J5Nm5HX2NDckR1dDJLZ1ZEOUlmNlV5NXFwQnN0ME1FR2FFSGhJODJEVUpmWWJTaGs2VnBRLUFMdjcyNzZTX2REclpLNV9uQjd4dVdjd3JIRHYzWHlyZGdjdURja3c1WmFQMmJoaEZqbFNJekpSMDFFcDZtdHhreTNlbg?oc=5","date":"2024-12-17","type":"pipeline","source":"Business Wire","summary":"Fresenius Kabi Launches Epinephrine Injection, USP Expanding U.S. Pharma Portfolio - Business Wire","headline":"Fresenius Kabi Launches Epinephrine Injection, USP Expanding U.S. Pharma Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNS2xXRG80UnJFRUduWlc0dHA0UlVYM2VoN2dhME9FVjJYMmhuZ1lKNG5FT0FIdWR2czcxaHFZYktiQzMtazJzTEg0c1J3V0xnN2JpcnRqY0JvX1c0MUpHTjJQcGpvZkRFZ2gyc0w3c2Jxbl9BYlZsWS1JbVM2ZzZGU21PdzQ2bFAxOExHdENTVEctSnEycUF5NXI3WkwyamJMVVJVYkpNeEN3aXRkNnNNLUUwNUt6a1NwVHo3VjdJRnlBM25CUjFtNm1leXJncjlhcjVtYkNZSWhTUjQ?oc=5","date":"2024-04-15","type":"regulatory","source":"BioSpace","summary":"Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S. - BioSpace","headline":"Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNdG1EdDdQUVJyVzNfZnhKVmNheUhidTA3bjVscEJUUkszb3QyNUUzQVNQT1NndHZVajlwckZFZHZzTzJPSjVGS1BiWEZKZERiUVVrR0pfMlV4S0pnODltaGlXM2RZZ1BUODIzYS1ONEFjOVdtTnBjTTVCd0hFWXZGZW0zOE80NjRNSWxzX0xGZXNmNVU0Vm9LckhmVTg0ZEpIb0RPangyUGhrTnF1Q3NVNU85YV95c1Z5c3o5RnhObTJ1S0ZrcFlzUjhEMFU?oc=5","date":"2024-01-30","type":"pipeline","source":"BioPharma APAC","summary":"Fresenius Kabi Launches Posaconazole Injection for Fungal Infection Prevention/Treatment - BioPharma APAC","headline":"Fresenius Kabi Launches Posaconazole Injection for Fungal Infection Prevention/Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOamI5UGZFRlgzdVFzcVF0YjlWQzJiQWtVMEU0Z2VVX1NxRUlyam1xV0Y3UHdzTDBpM2Y1a0U5UmtXRi0tY1Bxa1lLRTB0RUJDZi1KcmxZU195ZlZQNWxXUU9ZUy1VREhJbWEtc1pPcFZ2Y2g1U2wyTHdTVFk2ZmJVaWZucC10TUpHNDdXU3BUNlJMM2xIOWZmTU4xRHdYb0M3MWxQWk83T3Z3WlhrVWlfa3RQcHg4UWVzSnBVTzVPc24?oc=5","date":"2023-06-21","type":"patent","source":"Imaging Technology News","summary":"Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection - Imaging Technology News","headline":"Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQcHJOOWp2cktta0djcnVMN25aS3lDUGMzQWZIUGJ2MklvQzNtVXRsVTE0c19HaVV2dFN5TEd1Rm9WbUdnNlowMGIxa002VUUwMzJ0Uk1ZNi1XQWJUR1oyWGJJQTBrRVRMb3dWMzItemNoZks4OUM1R1JwZnl1b1ROMEpOTmJEUlY0NkUyOHc3TDJETzA5ckdKaw?oc=5","date":"2023-03-03","type":"pipeline","source":"Pharmaceutical Commerce","summary":"Fresenius Kabi Introduces Unit-of-Use 2D Barcodes - Pharmaceutical Commerce","headline":"Fresenius Kabi Introduces Unit-of-Use 2D Barcodes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNOGRSaWxfZlVXZDZkcTVvSU1JMHRTaTBXTmdDRWx2UmRRbVRvSXl3bnppUjl4Q2dVMXJRcDAxQTVxQVZ3M2dRZ0g5QjZDbS0yTklJWlNnWTY1VUdIWllHak5aMTBSTFptUVVQbmlhd00xbVRLZTBSQVdEd1pxU3BETW1PWHN4TDByRGlNWDI2UFlrMHRhbjFCUzlxZVMwOHpVdHJGTDRVUnc0NjhIUFVaYjNrMW1JWUV5NjIxZllhYURGQTY1VFlITXo0MlVYejhucWN2TW5sSktVeEk?oc=5","date":"2021-08-12","type":"pipeline","source":"Healthcare Packaging","summary":"Fresenius Kabi Goes Above and Beyond DSCSA Requirements with RFID - Healthcare Packaging","headline":"Fresenius Kabi Goes Above and Beyond DSCSA Requirements with RFID","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxObmN1UXNKYWFZTjMwTzEyWjlyeUhINzBNamlFQ3M3WWRKYzFWcGJObzZhWWJfazZtcFRZRXlWR0hJYXc2elNWZ1FKakx4UnNSWWI0b25QUGVGUkkwWndJSHpYM2s5ek1NUGRrWlB2dHBiNjhwTHB0cXBMaWgteU1MdFBSM0JRSmEwbHRac1FnMkQ1MXY3UkJjVTUyU2lTdw?oc=5","date":"2016-08-25","type":"pipeline","source":"BioPharma Dive","summary":"Fresenius Kabi invests $250M in manufacturing expansion - BioPharma Dive","headline":"Fresenius Kabi invests $250M in manufacturing expansion","sentiment":"neutral"},{"date":"2011-03-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2011-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2011-02-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"}],"patents":[{"drugName":"Lignospan Forte","drugSlug":"lidocaine-hydrochloride","patentNumber":"8759401","type":"Formulation","expiryDate":"2026-07-24","territory":"US","genericFilings":[]},{"drugName":"Voluven","drugSlug":"hydroxyethyl-starch-130/0.4","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Lignospan Forte","drugSlug":"lidocaine-hydrochloride","patentNumber":"8540665","type":"Method of Use","expiryDate":"2029-10-22","territory":"US","genericFilings":[]},{"drugName":"SmofKabiven","drugSlug":"parenteral-nutrition","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"EU","annualRevenue":800000000},{"drugName":"Unithroid","drugSlug":"levothyroxine-sodium","patentNumber":"9050307","type":"Formulation","expiryDate":"2031-08-06","territory":"US","genericFilings":[]},{"drugName":"Unithroid","drugSlug":"levothyroxine-sodium","patentNumber":"9168238","type":"Formulation","expiryDate":"2032-08-29","territory":"US","genericFilings":[]},{"drugName":"Unithroid","drugSlug":"levothyroxine-sodium","patentNumber":"9168239","type":"Formulation","expiryDate":"2032-08-29","territory":"US","genericFilings":[]},{"drugName":"Unithroid","drugSlug":"levothyroxine-sodium","patentNumber":"9006289","type":"Formulation","expiryDate":"2032-10-03","territory":"US","genericFilings":[]},{"drugName":"Unithroid","drugSlug":"levothyroxine-sodium","patentNumber":"9345772","type":"Formulation","expiryDate":"2035-02-27","territory":"US","genericFilings":[]},{"drugName":"Lignospan Forte","drugSlug":"lidocaine-hydrochloride","patentNumber":"9358338","type":"Method of Use","expiryDate":"2035-04-27","territory":"US","genericFilings":[]},{"drugName":"Lignospan Forte","drugSlug":"lidocaine-hydrochloride","patentNumber":"9370622","type":"Method of Use","expiryDate":"2035-09-28","territory":"US","genericFilings":[]},{"drugName":"Unithroid","drugSlug":"levothyroxine-sodium","patentNumber":"11154498","type":"Formulation","expiryDate":"2036-07-20","territory":"US","genericFilings":[]},{"drugName":"Unithroid","drugSlug":"levothyroxine-sodium","patentNumber":"11096913","type":"Formulation","expiryDate":"2037-02-28","territory":"US","genericFilings":[]},{"drugName":"Unithroid","drugSlug":"levothyroxine-sodium","patentNumber":"10537538","type":"Formulation","expiryDate":"2037-02-28","territory":"US","genericFilings":[]},{"drugName":"Unithroid","drugSlug":"levothyroxine-sodium","patentNumber":"10231931","type":"Formulation","expiryDate":"2038-03-23","territory":"US","genericFilings":[]},{"drugName":"Unithroid","drugSlug":"levothyroxine-sodium","patentNumber":"10406108","type":"Formulation","expiryDate":"2038-03-23","territory":"US","genericFilings":[]},{"drugName":"Unithroid","drugSlug":"levothyroxine-sodium","patentNumber":"11241382","type":"Method of Use","expiryDate":"2039-09-17","territory":"US","genericFilings":[]}],"drugCount":36,"phaseCounts":{"marketed":30,"phase_3":6},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Baxter International","B. Braun Melsungen","Grifols"],"therapeuticFocus":["Oncology","Critical Care","Gastroenterology"],"financials":{"source":"sec_edgar+yahoo","revenue":26717672249.399998,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":26717672249.399998},{"period":"2024-12-31","value":25644199561.199997},{"period":"2023-12-31","value":24608105682.6},{"period":"2022-12-31","value":25151266509.6}],"grossProfit":6649923845.4,"grossProfitHistory":[{"period":"2025-12-31","value":6649923845.4},{"period":"2024-12-31","value":6584510928.599999},{"period":"2023-12-31","value":5806564453.799999},{"period":"2022-12-31","value":6311178383.4}],"rdSpend":739399577.4,"rdSpendHistory":[{"period":"2025-12-31","value":739399577.4},{"period":"2024-12-31","value":748744279.8},{"period":"2023-12-31","value":772106035.8},{"period":"2022-12-31","value":746408104.1999999}],"sgaSpend":3367597127.3999996,"operatingIncome":2548066726.9199996,"operatingIncomeHistory":[{"period":"2025-12-31","value":2548066726.9199996},{"period":"2024-12-31","value":2421446009.3999996},{"period":"2023-12-31","value":1381847867.3999999},{"period":"2022-12-31","value":2116575093.6}],"netIncome":1476462979.1999998,"netIncomeHistory":[{"period":"2025-12-31","value":1476462979.1999998},{"period":"2024-12-31","value":550169353.8},{"period":"2023-12-31","value":-693844153.1999999},{"period":"2022-12-31","value":1602616461.6}],"eps":2.24,"epsHistory":[{"period":"2025-12-31","value":2.24},{"period":"2024-12-31","value":0.84},{"period":"2023-12-31","value":-1.05},{"period":"2022-12-31","value":2.44}],"cash":1526690754.6,"cashHistory":[{"period":"2025-12-31","value":1526690754.6},{"period":"2024-12-31","value":2389907638.7999997},{"period":"2023-12-31","value":2673752974.2},{"period":"2022-12-31","value":3000817558.2}],"totalAssets":48352994480.99999,"totalLiabilities":25263402938.399998,"totalDebt":13938791717.4,"equity":22315149331.199997,"operatingCashflow":3006657997.2,"operatingCashflowHistory":[{"period":"2025-12-31","value":3006657997.2},{"period":"2024-12-31","value":2858310846.6},{"period":"2023-12-31","value":5204999236.799999},{"period":"2022-12-31","value":4903632584.4}],"capex":-1748627436.6,"capexHistory":[{"period":"2025-12-31","value":-1748627436.6},{"period":"2024-12-31","value":-1238173068},{"period":"2023-12-31","value":-1502160910.8},{"period":"2022-12-31","value":-1393528745.3999999}],"freeCashflow":1258030560.6,"dividendsPaid":-798972055.1999999,"buybacks":0,"employees":177783,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":962504347.1999999,"ebit":1074640776,"ebitda":1441420345.1999998,"period":"2025-12-31","revenue":7190748496.799999,"epsBasic":null,"netIncome":421679695.79999995,"rdExpense":198574925.99999997,"epsDiluted":null,"grossProfit":1780165807.1999998,"operatingIncome":547132325.52},{"sga":864384971.9999999,"ebit":654129168,"ebitda":967176698.3999999,"period":"2025-06-30","revenue":6519098011.799999,"epsBasic":0.58,"netIncome":385468973.99999994,"rdExpense":191566399.2,"epsDiluted":0.58,"grossProfit":1703072012.3999999,"operatingIncome":654129168},{"sga":751080455.4,"ebit":802476318.5999999,"ebitda":1108515322.1999998,"period":"2025-03-31","revenue":6600864157.799999,"epsBasic":0.41,"netIncome":267492106.2,"rdExpense":163532292,"epsDiluted":0.41,"grossProfit":1648171885.8,"operatingIncome":802476318.5999999},{"sga":856208357.4,"ebit":726550611.5999999,"ebitda":1107347234.3999999,"period":"2024-12-31","revenue":6576334313.999999,"epsBasic":null,"netIncome":280341072,"rdExpense":206751540.6,"epsDiluted":null,"grossProfit":1652844236.9999998,"operatingIncome":547833178.1999999},{"sga":817661459.9999999,"ebit":572363022,"ebitda":881906288.9999999,"period":"2024-09-30","revenue":6208386656.999999,"epsBasic":0.58,"netIncome":380796622.79999995,"rdExpense":198574925.99999997,"epsDiluted":0.58,"grossProfit":1586263232.3999999,"operatingIncome":572363022}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":39.07,"previousClose":38.33,"fiftyTwoWeekHigh":52.96,"fiftyTwoWeekLow":38.16,"fiftyTwoWeekRange":"38.16 - 52.96","fiftyDayAverage":43.5,"twoHundredDayAverage":46.96,"beta":0.86,"enterpriseValue":37515342131.219246,"forwardPE":10,"priceToBook":1.11,"priceToSales":0.96,"enterpriseToRevenue":1.4,"enterpriseToEbitda":10.59,"pegRatio":0.77,"ebitda":3543277607.277619,"ebitdaMargin":13.2,"freeCashflow":2108106400.9817855,"operatingCashflow":3395631309.357619,"totalDebt":13906085782.303333,"debtToEquity":58.2,"currentRatio":1.26,"returnOnAssets":3.3,"returnOnEquity":7.8,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":14,"targetMeanPrice":55.08,"targetHighPrice":59,"targetLowPrice":48,"dividendRate":1.05,"payoutRatio":0.37,"fiveYearAvgDividendYield":1.15,"exDividendDate":1779667200,"insiderHeldPercent":27,"institutionHeldPercent":45.4,"sharesOutstanding":563237277,"floatShares":410560548,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":2.68,"epsForward":3.9,"revenuePerShare":40.81,"bookValue":35.12,"officers":[{"age":57,"name":"Mr. Michael  Sen","title":"CEO, President & Chairman of Management Board of Fresenius Management SE"},{"age":45,"name":"Ms. Sara Lisa Hennicken","title":"CFO & Member of the Management Board - Fresenius Management SE"},{"age":59,"name":"Mr. Pierluigi  Antonelli","title":"Member of Management Board of Fresenius Management SE & CEO of Fresenius Kabi"},{"age":49,"name":"Dr. Michael Sven Moser Ph.D.","title":"Member of Management Board of Fresenius Management SE"},{"age":58,"name":"Mr. Robert  Moller","title":"Member of the Management Board of Fresenius Management SE"},{"age":null,"name":"Mr. Nick  Stone","title":"Senior VP of Investor Relations & Head of Investor Relations - Fresenius Management SE"}],"industry":"Medical Care Facilities","irWebsite":"","website":"https://www.fresenius.com","phone":"49 6172 6080"}}